Patient should be ambulatory / upright 2 hours prior to sampling. Drug interactions to be noted: Potassium wasting diuretics, Spironolactone, Eplerenone, Amiloride and Triamterene should be discontinued at least for 4 weeks; Adrenergic blockers, Clonidine, Methyldopa, NSAIDs, Angiotensin-converting enzyme inhibitors, Angiotensin receptor blockers, Renin inhibitors and Dihydropyridine calcium channel antagonists should be discontinued for 2 weeks. If necessary to maintain hypertension control, patients should be treated with other antihypertensive medications like Verapamil slow-release, Hydralazine, Prazosin, Doxazosin & Terazosin that have lesser effects on Plasma renin & aldosterone levels. Any change in medication should be done in consultation with treating physician.
Technique: Chemiluminescence Immunoassay (CLIA)
Technique: EDTA Lavender Top -1 SST Yellow Top -1
Technique: 2-8°C, F (-20⁰C)
Sample Collection Instruction: Aldosterone/Renin ratio, Screening test for primary aldosteronism in higher risk groups of hypertensive patients
